核心观点3月21日,公司发布公告,拟与阿斯利康聚焦疫苗建立深度战略合作伙伴关系,并设立合资公司作为在中国开发创新疫苗的平台,面向中国和新兴市场供应疫苗。本次与阿斯利康的合作符合公司国际化发展战略,有助于公司引入国际领先的疫苗研发技术,增强自身创新能力。未来产品实现销售,将为公司业绩增长带来新增量。公司可借助阿斯利康的全球销售网络,推动自有疫苗产品拓宽海外市场,推动全球化业务发展。事件公司拟与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.